mon
JANUARY 22, 2018 / 5:41 pM
Stocks
hit record as senators reach deal to end shutdown
DJ: 26,214.60 +142.88 NAS: 7,408.03 +71.65 S&P: 2,832.97
+22.67 1/22
(Reuters) - U.S. stocks
advanced on Monday as each of Wall Street’s main scored records in the wake of
a deal by U.S. senators to end the federal government shutdown. Legislation to renew federal funding to the
government cleared a procedural hurdle in the Senate and was expected soon to
pass votes in the Senate and House of Representatives, allowing government to
re-open through Feb 8.
“You would think something like the threat of a government shutdown or an
actual government shutdown would serve as a catalyst to spook some weaker holders out of the
market,” said Eric Marshall, portfolio manager and director of research at
Hodges Capital Management in Dallas, Texas. “That hasn’t happened, which speaks to underlying strength of what we’re seeing
right now in equity
markets.”
Earnings growth of 12.4
percent is expected for the
quarter, according to Thomson Reuters data. Of the 55 companies in the S&P
500 that have reported earnings through Monday morning, 80 percent have topped
expectations, well above the 72 percent beat rate for the past four quarters.
The
Dow Jones Industrial Average .DJI rose 142.88 points, or 0.55 percent, to
26,214.6, the S&P 500 .SPX gained 22.67 points, or 0.81 percent, to
2,832.97 and the Nasdaq Composite .IXIC added 71.65 points, or 0.98 percent, to
7,408.03.
Halliburton Co (HAL.N) climbed 6.40 percent after posting a
much bigger-than-expected
quarterly profit in the fourth quarter, benefiting from a shale-driven
surge in U.S. oil production.
The Nasdaq biotech index .NBI rose 3.15 percent to notch its
best day since June 21 after a flurry of merger activity in the sector
with French drugmaker Sanofi (SASY.PA) and U.S.-based Celgene (CELG.O) splurging a combined total of more
than $20 billion. Shares in U.S.
hemophilia specialist Bioverativ (BIVV.O) soared 61.89 percent after Sanofi
agreed to buy the company for $11.6 billion.
Juno Therapeutics (JUNO.O) jumped 26.83 percent after Celgene
agreed to buy the biotech for about $9 billion in cash. In other M&A news, AIG (AIG.N) said it would buy reinsurer Validus
Holdings (VR.N) for $5.56 billion, sending the
target’s shares up 44.03 percent.
Industrial stocks were one of the few
laggards, as woes continued for General Electric (GE.N), down 0.55 after BofA-Merrill Lynch
downgraded its stock. GE fell below $16 for the first time since 2011 and is
down nearly 8 percent for the year. Shares
of Netflix Inc (NFLX.O), a major contributor to the recent
stock rally, closed up 3.23 percent ahead of its quarterly results and added to
gains in extended trading after its quarterly numbers were released.
Advancing issues outnumbered declining ones on the NYSE by a
1.70-to-1 ratio; on Nasdaq, a 1.38-to-1 ratio favored advancers. The S&P 500 posted 123 new 52-week highs
and 3 new lows; the Nasdaq Composite recorded 202 new highs and 16 new lows.
Volume on U.S. exchanges
was 6.56 billion shares,
above the 6.34 billion average for the full session over the last 20 trading
days.
No comments:
Post a Comment